Discussion items                                              

Item

Description

Mins

Owner

Notes & Actions

1Opening2 min

Welcome & Notification of Recording

2Hydration Subsumption (incl. less granular Clinical Drug)50 min
@Canada
@All
  • Proposal from Canada
  • Group discussion on options


Meeting Notes

Discussion on options proposed for managing hydration subsumption:

  1. Less granular Clinical Drug - beneficial for other reasons, but likely a more complex discussion and piece of work
  2. CGI - complex in terms of modelling, and a workaround that may be replaced by a less granular clinical drug
  3. Solvate modification to substances - presents good option to manage the current challenge. Areas such as concept definitions, role chains, PAIs that are also BoSS, and challenging substances need to be worked through.

Canada will share list of c.200 known hydrated substances - to be used by group to explore approach to option 3 and help identify possible challenging cases. Examples highlighted included choral hydrate, caffeine injection, pramipexole, tacrolimus.  

3Substances Co-Ordination Update8 minAlejandro Lopez Osornio 
  • Combined substances sheet link has been updated: HERE.
  • Update on substances in multiple extensions (circa. 80)
  • Update on substances in single extensions
4AOB
Update from Nicki on Patch Strength representation briefing note - It has now moved to implementation.
5Topic Backlog

  • Hydration Subsumption
  • Less Granular Clinical Drug
  • Elemental Substances (Matt, AUS)
  • Dose Form Intended Site v Route of Administration (BEL)
  • Substances Co-ordination
    • Step 1: Substances in multiple extensions
    • Step 2: Substances in one extension
    • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
  • Medication Stopped v Medication Discontinued (Karen, SI)
  • Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work)
  • Value range of a |Has container type| attribute (Linda, CA)
  • Drug extension MRCM attributes (CA, AUS)
  • Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
  • Group Input on Patch Strength Representation